Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 ...

Loss per share was $(0.58), falling short of analyst expectations by $(0.13), or 29.1% (GAAP, Q2 2025). - Research and development expenses rose to $60.2 million in Q2 2025, up from $23.8 million in ...

Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

In the second part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, explains how dual-action metabolic therapies can address clinical or tolerability gaps observed in ...

Once scorned as a cosmetic lifestyle disfigurement, obesity today is recognised as a chronic and progressive disease. From the altered metabolic deran.

I used to stare into my empty fridge every Tuesday night, ordering Chinese food again, wondering why I couldn’t just […] The post 25 Weekly Meal Plans That Will Actually Work for Your Real Life ...